EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Epidemiology and clinical management of cytomegalovirus infection in transplant recipients in Central and Eastern Europe – a physician survey

Alicja Dębska-Ślizień, Milena Todorović Balint, Radovan Vrhovac, Aleksandar Biljić Erski, Tina Roblek iD

Antiviral Therapy · 2026-04 · 31 (2)

DOI: 10.1177/13596535261440692 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Antiviral Therapy, online erschienen am 29.04.2026. Verfasst von Alicja Dębska-Ślizień und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nephrology, Transplantology and Internal Diseases, Medical University of Gdańsk, Gdańsk, Poland. Hauptthemen laut MEDLINE: Cytomegalovirus Infections, Antiviral Agents, Transplant Recipients, Organ Transplantation. Die Arbeit nennt 60 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Takeda Pharma OÜ.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Posttransplant cytomegalovirus (PT-CMV) infection remains a challenging complication and a major cause of morbidity and mortality in transplant recipients.

Methods

This cross-sectional study surveyed physicians treating solid organ and hematopoietic stem cell transplantation recipients from Central and Eastern European countries. Physician-reported CMV infection prevalence in transplant recipients, treatment regimens, and unmet needs for managing patients with refractory with/without resistance (R+/R-) PT-CMV infection were assessed.

Results

Overall, 164 physicians completed the survey, 23.8% of whom were nephrologists. Physicians estimated that 26.4% of patients who received a transplant in the past 12 months developed PT-CMV infection, of whom 12.9% had refractory R+/R- PT-CMV infection. On average, 66.5%, 16.5%, and 4.0% of physicians’ current patients with PT-CMV infection received first-, second-, and third- or later-line treatments, respectively. Physicians considered maintenance of CMV viremia clearance (94.5%), good symptom control (94.5%), and lack of renal toxicity (93.9%) as moderately-to-extremely important treatment attributes for managing PT-CMV infection. Compared with other available treatments, more physicians indicated oral valganciclovir to have a strong-to-complete association with these treatment attributes. Overall, 63.4% of physicians indicated some level of satisfaction with conventional refractory R+/R- PT-CMV treatments. However, 54.9% of physicians reported limited experience with newly approved therapies, such as maribavir. Most physicians considered limited treatment options as a major barrier for improving patient outcomes.

Conclusion

Survey findings of physicians treating transplant recipients in Central and Eastern Europe suggest the need for increased awareness of newly approved therapies with better efficacy and less toxicity for refractory R+/R- PT-CMV infection.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cytomegalovirus InfectionsAntiviral AgentsTransplant RecipientsOrgan TransplantationHumansCross-Sectional StudiesCytomegalovirusHematopoietic Stem Cell TransplantationSurveys and QuestionnairesPhysiciansEurope, EasternMaleEuropeFemalePrevalence

Stichwörter der Autor:innen

antiviral therapycytomegalovirus infectionhematopoietic stem cell transplantationphysician perspectiverefractorysolid organ transplantationsurvey

Substanzen

Antiviral Agents

Autor:innen und Institutionen

  • Department of Nephrology, Transplantology and Internal Diseases, Medical University of Gdańsk, Gdańsk, Poland.
  • Clinic of hematology, University Clinical Center of Serbia, Belgrade, Serbia.
  • Faculty of Medicine, University of Belgrade, Belgrade, Serbia.
  • Stem Cell Transplantation Unit, University Hospital Centre Zagreb, Zagreb, Croatia.
  • Takeda Pharmaceuticals, Belgrade, Serbia.
  • Takeda Pharmaceuticals, Ljubljana, Slovenia.

ORCID-Profile: Tina Roblek

Förderung

  • Takeda Pharma OÜ

Zitieren

APA

Dębska-Ślizień, A., Todorović Balint, M., Vrhovac, R., Biljić Erski, A., & Roblek, T. (2026). Epidemiology and clinical management of cytomegalovirus infection in transplant recipients in Central and Eastern Europe – a physician survey. Antiviral Therapy, 31(2). https://doi.org/10.1177/13596535261440692

Vancouver

Dębska-Ślizień A, Todorović Balint M, Vrhovac R, Biljić Erski A, Roblek T. Epidemiology and clinical management of cytomegalovirus infection in transplant recipients in Central and Eastern Europe – a physician survey. Antiviral Therapy. 2026;31(2). doi:10.1177/13596535261440692

BibTeX
@article{Dbskalizie2026,
  author = {Dębska-Ślizień, Alicja and Todorović Balint, Milena and Vrhovac, Radovan and Biljić Erski, Aleksandar and Roblek, Tina},
  title = {Epidemiology and clinical management of cytomegalovirus infection in transplant recipients in Central and Eastern Europe – a physician survey},
  journal = {Antiviral Therapy},
  year = {2026},
  volume = {31},
  number = {2},
  doi = {10.1177/13596535261440692}
}
Kostenlos starten →